

# Synthesis of Ribosylated 1,2,3-Triazole Derivatives

Zhong-Xu Ren, Xiao-Min Chen, Zhan-Jiang Li, and Zhi-Tang Huang

Center for Molecular Sciences, Institute of Chemistry, The Chinese Academy of Sciences,  
Beijing 100080, People's Republic of China

Received 5 March 2003

**ABSTRACT:** Ribosylated 1,2,3-triazole **4** and **5** were synthesized in moderate yields by the reaction of aroyl-substituted heterocyclic ketene amins **1** or **2** with 2,3,5-tri-*O*-benzoyl- $\beta$ -D-ribofuranosyl azide (**3**). Their structures were determined by elemental analyses and spectroscopic methods. © 2003 Wiley Periodicals, Inc. *Heteroatom Chem* 14:487–490, 2003; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/hc.10167

## INTRODUCTION

Heterocyclic ketene amins are versatile intermediates for the synthesis of a wide variety of new heterocycles and fused heterocycles [1,2]. The reactions of heterocyclic ketene amins with 1,3-dipolar reagents, such as azides [3–11], nitrile imines [12,13], benzonitrile oxides [14,15], or its precursor [16,17], have been reported. A series of polysubstituted 1,2,3-triazoles have been synthesized by the reaction of heterocyclic ketene amins with azides, and when glucopyranosyl azide was used, a kind of glucosylated 1,2,3-triazole derivatives were obtained [9,11] which were found to be biologically active [18]. Considering that the ribosides may change or enhance their biological activities, the ribosylated 1,2,3-triazole derivatives were synthesized. In this paper, we report the results of the reaction between

aroyl-substituted heterocyclic ketene amins and 2,3,5-tri-*O*- $\beta$ -D-ribofuranosyl azide.


## RESULTS AND DISCUSSION

The aroyl-substituted heterocyclic ketene amins **1** and **2** used were prepared by the reaction of aroyl-substituted ketene-*S,S*-diacetals with 1,3-propanediamine or *N*-methyl-1,3-propanediamine, according to the literature procedure [19]. Ketene amins **1** or **2** reacted with 2,3,5-tri-*O*-benzoyl- $\beta$ -D-ribofuranosyl azide (**3**) [20] to give the *N*-ribosylated triazoles **4** or **5** (Scheme 1). The reaction conditions, yields, and melting points of **4** and **5** are listed in Table 1.

The structures of compounds **4** and **5** were determined by IR,  $^1\text{H}$ , and  $^{13}\text{C}$  NMR and also by MS and elemental analyses. The constitutions of **4** and **5** were confirmed by MS and elemental analyses, which indicated that a reaction took place between **1** or **2** with **3** in 1:1 molar ratio, accompanied by the loss of 1 mol of water. The disappearance of the aroyl carbonyl absorption (ca.  $1610\text{ cm}^{-1}$ ) in the IR spectra and of the carbonyl signal ( $\delta$  ca. 180–190 ppm) in the  $^{13}\text{C}$  NMR of compounds **4** and **5**, the appearance of benzyloxy carbonyl bands/signals in the IR and NMR spectra, and the disappearance of the ethylenic proton signal in the  $^1\text{H}$  NMR spectra are all consistent with the structures shown for compounds **4** and **5**. The  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR signals, especially those of the ribofuranose ring, were assigned by  $^1\text{H}$ - $^1\text{H}$  and  $^1\text{H}$ - $^{13}\text{C}$  COSY spectrum of **4b**. The  $\beta$ -configuration of ribofuranosyl ring was confirmed by the  $\text{H}_1$ - $\text{H}_2$  coupling constants ( $J_{\text{H}_1, \text{H}_2} = 5.4\text{--}6.8\text{ Hz}$ ) for **4** and **5** [21].

Correspondence to: Zhi-Tang Huang; e-mail: huangzt@public.bta.net.cn.

Contract grant sponsor: National Science Foundation of China and Major State Basic Research Development Program.  
© 2003 Wiley Periodicals, Inc.



SCHEME 1

The above results are similar to those of the reaction of benzoyl-substituted heterocyclic ketene aminals with phenyl azides. The polysubstituted 1,2,3-triazoles are formed by the nucleophilic attack of the  $\alpha$ -carbon of the ketene aminal to the terminal nitrogen atom of the azide, the reaction then being completed by cyclocondensation and aromatization sequences [8].

### EXPERIMENTAL

Melting points are uncorrected. Microanalyses were carried out by the Analytical Laboratory of the Institute. Mass spectra were obtained on a KYKY-ZHT-5 instrument. IR spectra were recorded with Bruck IFS 2s spectrometer for KBr tablets. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on Varian 200 spectrometer in CDCl<sub>3</sub> with tetramethylsilane as the internal standard.

**TABLE 1** Reaction Conditions, Yields, and Melting Points of Compounds **4** and **5**

Compd.	Reaction Conditions		Yield <sup>a</sup> (%)	m.p. (°C)
	Temp. (°C)	Time (d)		
<b>4a</b>	35	4	62	95–97
<b>4b</b>	35	5	68	86–88
<b>4c</b>	35	4	75	82–84
<b>4d</b>	35	6	58	93–95
<b>4e</b>	35	6	60	105–107
<b>4f</b>	35	6	63	121–123
<b>5a</b>	35	8	53	89–91
<b>5b</b>	35	12	65	98–100
<b>5c</b>	35	8	70	80–82
<b>5d</b>	35	14	50	80–82

<sup>a</sup>Isolated yield.

### General Procedure for the Synthesis of Compounds **4** and **5**

A mixture of benzoyl-substituted heterocyclic ketene aminals **1** or **2** (1 mmol) and 2,3,5-tri-*O*-benzoyl- $\beta$ -D-ribofuranosyl azide (**3**) (1 mmol) in 20 ml anhydrous ethylene chloride was stirred at 35°C and monitored by TLC. After removal of solvent, the products were purified with a neutral aluminium oxide column, using chloroform as eluant.

*1*-(2,3,5-Tri-*O*-benzoyl- $\beta$ -D-ribofuranosyl)-4-(2-tetrahydropyrimidinyl)-5-phenyl-1,2,3-triazole (**4a**). IR (KBr): 3400 (N–H), 1729 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  8.00–7.20 (m, 20H, Ar-H), 6.52–6.47 (m, 1H, rib-H<sub>3</sub>), 6.16–6.10 (m, 1H, rib-H<sub>2</sub>), 6.01 (d, 2H,  $J_{H_1, H_2} = 6.8$  Hz, rib-H<sub>1</sub>), 5.73–5.60 (m, 1H, rib-H<sub>4</sub>), 4.37–4.04 (m, 2H, rib-H<sub>5</sub>), 3.35 (t, 4H,  $J = 5.7$  Hz, N–CH<sub>2</sub>), 1.77 (quin, 2H,  $J = 5.7$  Hz, C–CH<sub>2</sub>–C); <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  165.2, 164.8, 164.5, 147.7, 140.4, 137.5, 133.4, 130.5, 129.9, 129.8, 129.7, 129.5, 129.4, 129.1, 128.6, 128.5, 128.4, 128.3, 128.2, 127.8, 127.2, 125.8, 81.8, 68.4, 68.0, 66.6, 64.0, 41.5, 20.4; FABMS: 672 (M + 1)<sup>+</sup>. Anal. Calcd for C<sub>38</sub>H<sub>33</sub>N<sub>5</sub>O<sub>7</sub>: C, 67.95; H, 4.95; N, 10.43. Found: C, 67.32; H, 4.82; N, 9.80.

*1*-(2,3,5-Tri-*O*-benzoyl- $\beta$ -D-ribofuranosyl)-4-(2-tetrahydropyrimidinyl)-5-(*p*-methylphenyl)-1,2,3-triazole (**4b**). IR (KBr): 3416 (N–H), 1727 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.97–7.26 (m, 19H, Ar-H), 6.52–6.07 (m, 1H, rib-H<sub>3</sub>), 6.16–6.11 (m, 1H, rib-H<sub>2</sub>), 6.03 (d, 2H,  $J_{H_1, H_2} = 6.6$  Hz, rib-H<sub>1</sub>), 5.73–5.67 (m, 1H, rib-H<sub>4</sub>), 4.38–4.04 (m, 2H, rib-H<sub>5</sub>), 3.38 (t, 4H,  $J = 5.9$  Hz, N–CH<sub>2</sub>), 2.46 (s, 3H, CH<sub>3</sub>), 1.79 (quin, 2H,  $J = 5.9$  Hz, C–CH<sub>2</sub>–C); <sup>13</sup>C NMR (CDCl<sub>3</sub>):  $\delta$  165.1, 164.6, 164.3, 147.2, 140.6, 139.7, 137.2,

133.3, 130.2, 130.1, 129.6, 129.5, 129.1, 129.0, 128.7, 128.3, 128.2, 122.8, 81.4, 68.3, 67.9, 66.5, 63.8, 41.6, 21.4, 20.5; FABMS: 686 ( $M+1$ )<sup>+</sup>. Anal. Calcd for C<sub>39</sub>H<sub>35</sub>N<sub>5</sub>O<sub>7</sub>: C, 68.31; H, 5.15; N, 10.21. Found: C, 68.26; H, 5.22; N, 9.31.

*1-(2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl)-4-(2-tetrahydropyrimidinyl)-5-(p-methoxyphenyl)-1,2,3-triazole (4c)*. IR (KBr): 3429 (N–H), 1729 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.97–7.00 (m, 19H, Ar-H), 6.52–6.48 (m, 1H, rib-H<sub>3</sub>), 6.16–6.11 (m, 1H, rib-H<sub>2</sub>), 6.03 (d, 2H, *J*<sub>H<sub>1</sub>,H<sub>2</sub></sub> = 6.6 Hz, rib-H<sub>1</sub>), 5.75–5.68 (m, 1H, rib-H<sub>4</sub>), 4.38–4.09 (m, 2H, rib-H<sub>5</sub>), 3.89 (s, 3H, OCH<sub>3</sub>), 3.37 (t, 4H, *J* = 5.5 Hz, N–CH<sub>2</sub>), 1.79 (quin, 2H, *J* = 5.5 Hz, C–CH<sub>2</sub>–C); <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 165.2, 164.7, 164.5, 160.8, 147.9, 140.0, 137.5, 133.4, 133.3, 132.0, 129.7, 129.6, 129.5, 129.1, 128.6, 128.4, 128.3, 128.2, 117.4, 114.0, 81.7, 68.4, 68.0, 66.7, 64.0, 55.3, 41.5, 20.4; FABMS: 702 ( $M+1$ )<sup>+</sup>. Anal. Calcd for C<sub>39</sub>H<sub>35</sub>N<sub>5</sub>O<sub>8</sub>: C, 66.75; H, 5.03; N, 9.98. Found: C, 66.80; H, 5.13; N, 9.88.

*1-(2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl)-4-(2-tetrahydropyrimidinyl)-5-(p-chlorophenyl)-1,2,3-triazole (4d)*. IR (KBr): 3416 (N–H), 1732 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.04–7.22 (m, 19H, Ar-H), 6.52–6.24 (m, 1H, rib-H<sub>3</sub>), 6.18–6.12 (m, 1H, rib-H<sub>2</sub>), 6.00 (d, 2H, *J*<sub>H<sub>1</sub>,H<sub>2</sub></sub> = 6.4 Hz, rib-H<sub>1</sub>), 5.74–5.67 (m, 1H, rib-H<sub>4</sub>), 4.36–4.05 (m, 2H, rib-H<sub>5</sub>), 3.32 (t, 4H, *J* = 5.5 Hz, N–CH<sub>2</sub>), 1.72 (quin, 2H, *J* = 5.5 Hz, C–CH<sub>2</sub>–C); <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 165.2, 164.7, 164.4, 147.4, 140.7, 136.3, 136.0, 133.4, 133.3, 133.0, 131.9, 129.7, 129.5, 129.4, 129.0, 128.9, 128.7, 128.4, 128.3, 128.2, 127.8, 124.3, 81.7, 68.3, 67.8, 66.5, 63.9, 41.5, 20.4; FABMS: 706 ( $M+1$ )<sup>+</sup>. Anal. Calcd for C<sub>38</sub>H<sub>32</sub>ClN<sub>5</sub>O<sub>7</sub>: C, 64.63; H, 4.57; N, 9.92. Found: C, 64.53; H, 4.69; N, 9.45.

*1-(2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl)-4-(2-tetrahydropyrimidinyl)-5-(p-fluorophenyl)-1,2,3-triazole (4e)*. IR (KBr): 3430 (N–H), 1730 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.96–7.16 (m, 19H, Ar-H), 6.51–6.47 (m, 1H, rib-H<sub>3</sub>), 6.15–6.10 (m, 1H, rib-H<sub>2</sub>), 5.98 (d, 2H, *J*<sub>H<sub>1</sub>,H<sub>2</sub></sub> = 6.1 Hz, rib-H<sub>1</sub>), 5.75–5.68 (m, 1H, rib-H<sub>4</sub>), 4.37–4.08 (m, 2H, rib-H<sub>5</sub>), 3.38 (t, 4H, *J* = 5.2 Hz, N–CH<sub>2</sub>), 1.82 (quin, 2H, *J* = 5.2 Hz, C–CH<sub>2</sub>–C); <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 165.2, 164.7, 164.4, 147.2, 140.8, 136.3, 133.4, 133.3, 132.8, 132.6, 129.7, 129.6, 129.5, 129.3, 129.2, 129.0, 128.8, 128.4, 128.3, 122.0, 115.8, 115.3, 81.7, 68.3, 67.9, 66.6, 64.0, 41.6, 20.5; FABMS: 690 ( $M+1$ )<sup>+</sup>. Anal. Calcd for C<sub>38</sub>H<sub>32</sub>FN<sub>5</sub>O<sub>7</sub>: C, 66.18; H, 4.68; N, 10.15. Found: C, 65.76; H, 4.75; N, 10.37.

*1-(2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl)-4-(2-tetrahydropyrimidinyl)-5-(p-bromophenyl)-1,2,3-triazole (4f)*. IR (KBr): 3420 (N–H), 1730 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.96–7.20 (m, 19H, Ar-H), 6.53–6.49 (m, 1H, rib-H<sub>3</sub>), 6.17–6.12 (m, 1H, rib-H<sub>2</sub>), 5.97 (d, 2H, *J*<sub>H<sub>1</sub>,H<sub>2</sub></sub> = 6.6 Hz, rib-H<sub>1</sub>), 5.75–5.68 (m, 1H, rib-H<sub>4</sub>), 4.36–4.09 (m, 2H, rib-H<sub>5</sub>), 3.37 (t, 4H, *J* = 5.7 Hz, N–CH<sub>2</sub>), 1.78 (quin, 2H, *J* = 5.7 Hz, C–CH<sub>2</sub>–C); <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 165.2, 164.7, 164.4, 147.1, 140.9, 136.2, 133.5, 133.4, 133.3, 132.2, 131.6, 129.7, 129.6, 129.5, 129.0, 128.5, 128.3, 125.0, 124.4, 81.7, 68.4, 67.9, 66.5, 64.0, 41.6, 20.5; FABMS: 750 ( $M+1$ )<sup>+</sup>. Anal. Calcd for C<sub>38</sub>H<sub>32</sub>BrN<sub>5</sub>O<sub>7</sub>: C, 60.81 H, 4.30; N, 9.33. Found: C, 60.73; H, 4.68; N, 8.79.

*1-(2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl)-4-(N-methyl-2-tetrahydropyrimidinyl)-5-phenyl-1,2,3-triazole (5a)*. IR (KBr): 1730 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.00–7.20 (m, 20H, Ar-H), 6.57–6.53 (m, 1H, rib-H<sub>3</sub>), 6.19 (d, 2H, *J*<sub>H<sub>1</sub>,H<sub>2</sub></sub> = 5.9 Hz, rib-H<sub>1</sub>), 6.12–6.06 (m, 1H, rib-H<sub>2</sub>), 5.73–5.67 (m, 1H, rib-H<sub>4</sub>), 4.42–4.14 (m, 2H, rib-H<sub>5</sub>), 3.40 (t, 2H, *J* = 5.7 Hz, N–CH<sub>2</sub>), 3.20 (t, 2H, *J* = 5.7 Hz, N–CH<sub>2</sub>), 2.60 (s, 3H, N–CH<sub>3</sub>), 1.88 (quin, 2H, *J* = 5.7 Hz, C–CH<sub>2</sub>–C); <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 165.3, 164.7, 164.6, 149.8, 140.1, 137.2, 133.4, 133.3, 129.9, 129.8, 129.7, 129.6, 129.5, 129.3, 129.2, 128.9, 128.7, 128.4, 128.3, 128.2, 125.6, 122.5, 82.3, 68.4, 67.8, 66.7, 64.0, 48.0, 44.2, 39.2, 21.4; FABMS: 686 ( $M+1$ )<sup>+</sup>. Anal. Calcd for C<sub>39</sub>H<sub>35</sub>N<sub>5</sub>O<sub>7</sub>: C, 68.31; H, 5.15; N, 10.21. Found: C, 68.34; H, 5.36; N, 9.74.

*1-(2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl)-4-(N-methyl-2-tetrahydropyrimidinyl)-5-(p-methylphenyl)-1,2,3-triazole (5b)*. IR (KBr): 1730 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.98–7.20 (m, 19H, Ar-H), 6.58–6.54 (m, 1H, rib-H<sub>3</sub>), 6.19 (d, 2H, *J*<sub>H<sub>1</sub>,H<sub>2</sub></sub> = 5.6 Hz, rib-H<sub>1</sub>), 6.12–6.06 (m, 1H, rib-H<sub>2</sub>), 5.75–5.69 (m, 1H, rib-H<sub>4</sub>), 4.42–4.16 (m, 2H, rib-H<sub>5</sub>), 3.40 (t, 2H, *J* = 5.6 Hz, N–CH<sub>2</sub>), 3.19 (t, 2H, *J* = 5.6 Hz, N–CH<sub>2</sub>), 2.60 (s, 3H, N–CH<sub>3</sub>), 2.45 (s, 3H, CH<sub>3</sub>), 1.87 (quin, 2H, *J* = 5.6 Hz, C–CH<sub>2</sub>–C); <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 165.2, 164.7, 164.6, 149.8, 141.6, 140.0, 137.1, 133.3, 133.2, 129.7, 129.6, 129.5, 129.3, 129.1, 128.5, 128.3, 128.2, 128.1, 122.5, 82.1, 68.3, 67.7, 66.6, 63.8, 47.9, 44.2, 39.0, 21.4, 21.3; FABMS: 700 ( $M+1$ )<sup>+</sup>. Anal. Calcd for C<sub>40</sub>H<sub>37</sub>N<sub>5</sub>O<sub>7</sub>: C, 68.66; H, 5.33; N, 10.01. Found: C, 68.70; H, 5.39; N, 9.77.

*1-(2,3,5-Tri-O-benzoyl-β-D-ribofuranosyl)-4-(N-methyl-2-tetrahydropyrimidinyl)-5-(p-methoxyphenyl)-1,2,3-triazole (5c)*. IR (KBr): 1730 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.06–7.00 (m, 19H, Ar-H), 6.59–6.55 (m, 1H, rib-H<sub>3</sub>), 6.17 (d, 2H, *J*<sub>H<sub>1</sub>,H<sub>2</sub></sub> = 5.6 Hz, rib-H<sub>1</sub>), 6.14–6.08 (m, 1H, rib-H<sub>2</sub>), 5.75–5.69 (m,

1H, rib-H<sub>4</sub>), 4.43–4.16 (m, 2H, rib-H<sub>5</sub>), 3.88 (s, 3H, OCH<sub>3</sub>), 3.40 (t, 2H, *J* = 5.5 Hz, N–CH<sub>2</sub>), 3.22 (t, 2H, *J* = 5.5 Hz, N–CH<sub>2</sub>), 2.63 (s, 3H, N–CH<sub>3</sub>), 1.88 (quin, 2H, *J* = 5.5 Hz, C–CH<sub>2</sub>–C); <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 165.4, 164.8, 164.7, 160.9, 150.3, 140.8, 137.4, 133.4, 133.3, 132.7, 131.1, 129.8, 129.7, 129.6, 129.2, 128.9, 128.7, 128.4, 128.3, 117.3, 114.4, 113.0, 82.4, 68.4, 67.7, 66.8, 64.0, 55.3, 48.1, 43.7, 39.3, 21.2; FABMS: 716 (M+1)<sup>+</sup>. Anal. Calcd for C<sub>40</sub>H<sub>37</sub>N<sub>5</sub>O<sub>8</sub>: C, 67.12; H, 5.21; N, 9.78. Found: C, 67.11; H, 5.18; N, 9.53.

1-(2,3,5-Tri-*O*-benzoyl-β-D-ribofuranosyl-4-(*N*-methyl-2-tetrahydropyrimidinyl)-5-(*p*-chlorophenyl)-1,2,3-triazole (**5d**). IR (KBr): 1730 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.00–7.20 (m, 19H, Ar-H), 6.57–6.53 (m, 1H, rib-H<sub>3</sub>), 6.14 (d, 2H, *J*<sub>H<sub>1</sub>,H<sub>2</sub></sub> = 5.4 Hz, rib-H<sub>1</sub>), 6.13–6.07 (m, 1H, rib-H<sub>2</sub>), 5.75–5.69 (m, 1H, rib-H<sub>4</sub>), 4.40–4.16 (m, 2H, rib-H<sub>5</sub>), 3.38 (t, 2H, *J* = 5.4 Hz, N–CH<sub>2</sub>), 3.20 (t, 2H, *J* = 5.4 Hz, N–CH<sub>2</sub>), 2.64 (s, 3H, N–CH<sub>3</sub>), 1.86 (quin, 2H, *J* = 5.4 Hz, C–CH<sub>2</sub>–C); <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 165.2, 164.6, 164.5, 149.5, 141.9, 136.1, 133.4, 133.3, 133.2, 131.0, 129.6, 129.5, 129.4, 129.3, 129.1, 129.0, 128.6, 128.4, 128.3, 128.2, 128.0, 124.0, 82.3, 68.2, 67.5, 66.5, 63.9, 47.9, 44.1, 39.1, 21.2; FABMS: 720 (M+1)<sup>+</sup>. Anal. Calcd for C<sub>39</sub>H<sub>34</sub>ClN<sub>5</sub>O<sub>7</sub>: C, 65.05; H, 4.76; N, 9.72. Found: C, 65.30; H, 5.60; N, 9.65.

## REFERENCES

- [1] Huang, Z.-T.; Wang, M.-X. *Heterocycles* 1994, 37, 1233.
- [2] Wang, M.-X.; Huang, Z.-T. *Prog Natural Sci* 2002, 12, 249.
- [3] Bolis, G.; Pocar, D.; Stradi, R.; Trimarco, P. *J Chem Soc, Perkin Trans 1* 1977, 2365.
- [4] Viswanathau, N. I.; Balakrishnan, V. *J Chem Soc, Perkin Trans 1* 1979, 2361.
- [5] Fioravanti, S.; Loreto, M. A.; Pellacani, L.; Tardella, P. A. *Heterocycles* 1987, 25, 433.
- [6] Chakrasali, R. T.; Ila, H.; Junjappa, H. *Synthesis* 1988, 851.
- [7] Huang, Z.-T.; Wang, M.-X. *Chin Chem Lett* 1990, 1, 5.
- [8] Huang, Z.-T.; Wang, M.-X. *J Org Chem* 1992, 57, 184.
- [9] Chen, X.-M.; Li, Z.-J.; Ren, Z.-X.; Huang, Z.-T. *Carbohydr Res* 1999, 315, 262.
- [10] Liu, B.; Wang, M.-X.; Wang, L.-B.; Huang, Z.-T. *Heteroatom Chem* 2000, 11, 389.
- [11] Yang, Q.; Li, Z.-J.; Chen, X.-M.; Huang, Z.-T. *Heteroatom Chem* 2002, 13, 242.
- [12] Poscar, D.; Rossi, L. M.; Stradi, R. *Synthesis* 1976, 684.
- [13] Liu, B.; Wang, M.-X.; Huang, Z.-T. *Tetrahedron Lett* 1999, 40, 7399.
- [14] Rajappa, S.; Advani, B. G.; Sreenivasau, R. *Synthesis* 1974, 656.
- [15] Huang, Z.-T.; Wang, M.-X. *Synth Commun* 1991, 21, 1909.
- [16] Huang, Z.-T.; Wang, M.-X. *Synth Commun* 1991, 21, 1167.
- [17] Liu, B.; Wang, M.-X.; Huang, Z.-T. *J Chem Res, Synop* 2000, 330.
- [18] Huang, Z.-T.; Li, Z.-J.; Chen, X.-M.; Ren, Z.-X.; Wang, M.-X.; Liu, B.; Wang, L.-B.; Wang, H.-T. *Chinese Patent No. ZL 96107062.5*, 2001.
- [19] Huang, Z.-T.; Liu, Z.-R. *Synth Commun* 1989, 19, 943.
- [20] Szarek, W. A.; Achmatowicz, O. Jr.; Plenkiewicz, J.; Radatus, B. K. *Tetrahedron* 1978, 34, 1427.
- [21] Kim, C.-H.; Marquez, V. E. *J Org Chem* 1987, 52, 1979.